The role of GH in the regulation of fetal growth and metabolism in late gestation is not well defined. The aim of this study was to determine the effects of exogenous GH infusion on fetal growth and feto-placental metabolism in the normally growing late-gestation fetal sheep. Eleven fetuses received pulsatile GH infusion (3·5 mg/day) for 10 days while 12 control fetuses received vehicle. The GH infusion was given as a continuous infusion (2·5 mg/day) plus an additional pulsatile component (30 pulses equivalent to 1 mg/day) designed to mimic the natural pattern of GH secretion. Fetal GH infusion raised the circulating fetal concentrations of GH threefold, but did not change fetal concentrations of IGF-I, IGF-binding protein-3, insulin or ovine placental lactogen. GH-treated fetuses had blood urea concentrations 15% lower than controls (P<0·05) and glucose uptake 18% lower per kg fetal weight (P=0·06). There were no other differences attributable to fetal GH infusion in feto-placental metabolism, placental function or placental blood flow. GHtreated fetuses were larger than controls at postmortem (weight+13%, P<0·01; girth+5%, P<0·01; crown-rump length+3%, P<0·05). However, there were no differences between groups in measures of fetal growth (increment in chest girth and hindlimb length). GH-treated fetuses had heavier mothers and when maternal weight was included as a covariate in the analysis, there was no significant difference between treatment groups that could be attributed to GH treatment. GH infusion to normal fetal sheep does not appear to have a significant effect on feto-placental metabolism or fetal growth.
Introduction
Growth hormone (GH) has been shown to be a major endocrine regulator of postnatal growth and intermediary metabolism. However, its role in fetal life is less clear. Despite general acceptance of the dogma that GH does not regulate fetal growth in utero, there is increasing experimental evidence that GH may have at least some role in fetal growth in late gestation. GH-deficient dwarf rat fetuses have proportionately reduced body size (Kim et al. 1993) , while human fetuses with congenital GH deficiency are born relatively short (Gluckman et al. 1992) . In fetal sheep, hypophysectomy results in reduced length of the limbs and long bones which was not reversed by thyroid hormone replacement (Mesiano et al. 1987) , although the replacement may not have been completely adequate in this study.
There is also indirect evidence that fetal GH may have a role in feto-placental metabolism. Hypophysectomised fetal sheep have markedly increased fat deposition which is reversed by fetal GH replacement using a crude pituitary preparation (Stevens & Alexander 1986) . GH receptor mRNA is present in both hepatic and extrahepatic tissues in the late-gestation fetal sheep, including muscle and kidney (Klempt et al. 1993) . Circulating GH concentrations in late-gestation fetal sheep are also sensitive to factors similar to those thought to be important for GH regulation in postnatal life, including GH-releasing hormone (Gluckman 1984) , somatostatin (Gluckman et al. 1979) , free fatty acids (Bassett & Gluckman 1987 ) and undernutrition (Bauer et al. 1995) . GH in the maternal circulation may also influence placental function and feto-placental substrate distribution .
Despite this indirect evidence for possible roles of GH in fetal life, we are not aware of a study directly investigating the effects of additional fetal GH administration in utero. We therefore undertook this study to determine the effects of 10 days of exogenous GH infusion on fetal growth and feto-placental metabolism in normal lategestation fetal sheep. GH was infused in a pulsatile fashion to mimic the normal pattern of GH secretion in the fetal lamb (Bauer et al. 1995) .
Materials and Methods

Animals
Twenty-three Romney Dorset cross-bred ewes with singleton pregnancies of known gestational age were brought to the laboratory at approximately 105 days of gestation. They were housed in individual metabolic cages with free access to water and concentrates.
At 115 days (range 113-117 days) ewes underwent surgery as described previously . Briefly, hysterotomy was performed under general anaesthetic. Catheters were placed in the fetal femoral artery and vein via the tarsal vessels and the common umbilical vein via a para-umbilical incision. Two growth-measuring devices (growth catheters) were placed, one around each half of the fetal chest from sternum to spine (Mellor & Murray 1982) . Catheters were also placed in the uterine vein via the utero-ovarian vein draining the pregnant horn, and maternal carotid artery and jugular vein and the maternal femoral artery and vein via the tarsal vessels.
Antibiotics (250 ml streptomycin and 250 ml penicillin; Streptopen, Pitman Moore, Upper Hutt, New Zealand) were given intramuscularly to the ewe and 80 mg gentamycin intravenously to the fetus at the time of surgery and thereafter daily for the next 3 days. Catheters were flushed on alternate days with saline containing 10 IU/ml heparin. Growth catheters were measured twice daily after the ewe had been standing quietly for several minutes, and the mean of the two measurements was recorded.
At the end of the experiment (125-128 days) ewes were killed with an overdose of phenobarbitone. The uterus and its contents were dissected, weighed and measured. The position of all catheters was confirmed. All procedures were approved by the Institutional Animal Ethics Committee.
Experimental procedures
As soon as ewes had recovered consciousness after anaesthesia, fetuses in the GH treatment group began a 10-day pulsatile intravenous infusion of recombinant bovine GH (batch no. PR003; American Cyanamid, Princeton, NJ, USA). The GH was freshly prepared in carbonatebuffered saline, pH 9·4 (containing 145 mM NaCl, 31·5 mM NaHCO 3 , 10·7 mM Na 2 CO 3 ). The total daily dose was 3·5 mg, given as a continuous infusion of 2·5 mg (1 ml/h) plus an additional 1 mg divided as 30 superimposed pulses (330 µl/pulse). This pulsatile infusion was designed to mimic the natural secretion of GH (Bauer et al. 1995) . Control animals received an identical volume of the vehicle (carbonate-buffered saline). Blood samples (4 ml) were taken from the fetus and ewe in the morning before feeding on alternate days for metabolic and hormone measurements. On day 7, five samples were taken at 15-min intervals for measurement of mean GH concentration.
On day 10, GH feto-placental substrate uptakes were measured in five pairs of samples taken over an hour starting 2·5 h after cessation of the GH infusion. The GH infusion had to be stopped as fetal venous access was limited. A solution containing 110 mg antipyrine, 750 µCi 3-O- [methyl- 3 H]glucose and 120 µCi [ 14 C]urea in normal saline was infused via a 0·45 µm filter to the fetus via the fetal venous catheter at 3 ml/h for 3·5 h after a 5 ml bolus. After 150 min of infusion to establish a steady state, five sets of blood samples were taken at 15-min intervals. Each set consisted of samples taken from the maternal artery (2·7 ml), uterine vein (2·7 ml), umbilical vein (1·3 ml) and fetal artery (1·3 ml). All blood samples for metabolic measurements were aliquoted into Eppendorf tubes on ice and immediately frozen at -70 C until assay. Blood for hormone and free fatty acid measurements was centrifuged at 4 C and plasma separated and frozen at -70 C until assay. Samples for blood gas measurements were kept in capped syringes on ice until measurements were made within 30 min using a blood gas analyser (Chiron M845; Chiron Corporation, Emeryville, CA, USA).
Assays
Glucose (Kunst et al. 1984) and urea (Kerscher & Ziegenhorn 1985) were measured by standard enzymatic colorimetric methods modified for assay using a 96-well plate reader (Ashour et al. 1987) . Lactate was measured in microplates using an enzymatic procedure based on the reduction of NAD. Amino nitrogen was assayed by colorimetric reaction with -napthoquinone sulphonate (Evans et al. 1993) . Free fatty acids were measured by a modification of a commercial kit assay (Oliver et al. 1995) . Antipyrine was measured in duplicate by HPLC (Pimentel et al. 1986) . H]glucose activities were determined in duplicate aliquots of blood deproteinised with sulphuric acid and sodium tungstate and counted in a dual channel liquid scintillation counter (Rak-Beta model 1219; LKB Wallac, Turku, Finland) with external standard quench correction for 10 min or to a d.p.m. error of less than 3%. Insulin-like growth factor-I (IGF-I) was measured by double-antibody radioimmunoassay (RIA) after acid-ethanol cryoprecipitation extraction validated for fetal sheep plasma (Breier et al. 1994a) . Insulin (Oliver et al. 1993 ) and ovine placental lactogen (Oliver et al. 1992) were measured by RIA. Ovine IGF-binding protein-3 (IGFBP-3) was measured by RIA .
Data analysis
Blood oxygen content was calculated from measured haemoglobin, oxygen saturation, and p0 2 (Gull & Charlton 1993) . Blood flows were calculated from measuring antipyrine concentrations according to the Fick principle (Meschia et al. 1966) . Uptakes of oxygen, glucose, and lactate were calculated for the uterus and its contents (referred to as uterine uptake=maternal artery uterine vein concentration difference uterine blood flow), fetus (umbilical vein femoral artery concentration difference umbilical blood flow) and placenta (uterine uptake fetal uptake (Kulhanek et al. 1974 , Stacey et al. 1978 . Fetal urea production rate was calculated as the product of [ 14 C]urea clearance and the (fetal artery maternal artery) urea concentration difference (Gresham et al. 1972 , Battaglia & Meschia 1986 ). All uptakes are expressed relative to tissue weights, i.e. fetal uptakes per kg fetus, placental uptakes per kg placenta and uterine uptakes per kg uterus and contents.
All baseline measurements and postmortem measurements were compared using unpaired t-tests and analysis of covariance as appropriate. Metabolite and hormone concentrations over the period of the study were tested for GH effects by repeated measures analysis of variance. Not all data were available for every animal at each time-point, largely because catheters failed to sample. Differences in growth rates (chest girth increments) were tested using regression analysis as described previously (Harding 1997) .
All values are given as the means ... Statistical analyses were carried out using the SPSS software package (SPSS version 7·0; SPSS Inc., Chicago, IL, USA).
Results
Fetal GH infusion attained a pulsatile plasma GH profile (Fig. 1) , and raised mean circulating fetal GH concentrations threefold (Table 1) . Maternal GH concentrations were not changed by fetal GH treatment. Fetal and maternal circulating concentrations of IGF-I, IGFBP-3, insulin and placental lactogen were not altered by fetal GH infusion (Table 1) .
GH-treated fetuses had lower blood urea concentrations than controls and higher maternal oxygen concentrations.
There were no differences between groups in fetal or maternal blood glucose, lactate, amino nitrogen or fatty acid concentrations (Table 2) .
There was no difference between the GH-treated and control group in umbilical blood flow (174 11 GH profile of an individual fetus on day 7 of GH infusion. GH was infused at a constant rate of 2·5 mg/fetus per day. GH pulses (arrows) were superimposed at 48-min intervals (1 mg/fetus per day). Samples for GH analysis were taken every 15 min. At the end of the experiment, GH-treated fetuses were found to be larger than controls. They were heavier, longer, had greater girths and heavier liver, kidney, gut, thymus and placenta (Table 4) . When expressed per kg fetal weight, the GH-treated fetuses had relatively smaller brains, hearts and pituitaries but no differences were found in any other organ weights or body measurements.
However, we found that GH-treated animals had heavier mothers and the fetuses were larger at surgery, as indicated by fetal limb length measurements at that time (Table 5 ). There was also a trend towards more male fetuses in the GH-treated group (80 vs 42%, P=0·07). Fetal size was directly correlated with maternal weight over the whole group of animals (Table 6 ). When this was taken into account by including maternal weight as a covariate, fetal size and organ weights were no longer significantly different between groups at postmortem. The effect of fetal sex was not significant when it was added to the model. Furthermore, fetal growth rate as measured by increment in fetal girth was not changed by fetal GH treatment (6·8 0·8 vs 6·2 0·5 mm/day). Increment in fetal hindlimb length between surgery and postmortem was also not affected by GH administration (1·9 1·4 vs 3·3 0·4 cm). Thus the differences between groups at postmortem were most likely due to different initial sizes rather than the effects of GH treatment.
Discussion
The findings of this study illustrate the importance of careful assessment of the equivalence of experimental groups, and the risks of interpreting increased final size as evidence of increased growth. Fetuses in the GH-treated groups were heavier, longer and had increased weight of a number of organs compared with control animals. However, longitudinal measures of fetal growth (increment in girth and limb length) were not affected by GH treatment. Careful data analysis revealed that this paradox was explained by the observation that the GH-treated fetuses had heavier mothers and longer limbs at the time of surgery. The relationship between fetal size and maternal constraint, which is a function of maternal size, is well recognised (Heinrich 1992 , Morel et al. 1994 ). Thus it is most likely, since the groups differed at the beginning of the experiment, that the differences in outcome were not due to fetal GH therapy. The failure of bovine GH treatment to increase growth in fetal sheep cannot be ascribed to lack of biological activity of the bovine GH preparation used, since the same preparation induced the known metabolic and endocrine responses in adult sheep (Hennies et al. 1998) .
In the rat, responses to GH have been shown to vary depending on the pattern of GH administration. GH injections have a more pronounced effect on total body weight gain, while a constant infusion of GH leads to selective organ growth and reduction in size of fat pads (Clark et al. 1995 (Clark et al. , 1996 . The importance of pulsatile GH secretion in the fetal sheep is still unresolved. However, the pattern of circulating GH in our GH-treated fetuses was clearly pulsatile and in good agreement with the GH pattern we have reported in normally growing fetal sheep of similar gestational age (Bauer et al. 1995) . Thus it is unlikely that the lack of effect in the present study is due to lack of GH pulsatility.
We started GH treatment immediately after surgery in order to maximise duration of treatment. It is possible that post-operative stress meant that the fetuses underwent a period of relative GH resistance, and that this may have contributed to the absence of observed response to GH treatment. However, there were no observed trends over the period of the study in any of the monitored parameters (fetal blood gases, metabolite and hormone concentrations) suggestive of resolving post-operative stress. There was also no suggestion of fetal growth rate, measured by girth increment, diverging between the groups over time, as would be expected if GH did influence fetal growth and a period of hormone resistance was resolving postoperatively.
For practical reasons, placental function was studied over an hour beginning 2·5 h after GH treatment had been stopped. It is theoretically possible that the cessation of GH infusion before the study contributed to the lack of observed differences between groups. However, there were no observable trends over time in any of the parameters measured in the five sets of samples taken during the study. This suggests that there was not an observable effect due to declining GH levels over this period. Furthermore, the aspect of placental function which has been shown to respond to maternal GH treatment (placental diffusion capacity, measured by [ 14 C]urea clearance; Harding et al. 1997 ) is determined by structural characteristics of the placenta such as surface area and barrier thickness. These characteristics are not likely to have changed over the 3·5-h period of withdrawal of GH treatment in our study. In addition, the lack of effect of GH treatment on fetal growth, metabolic and endocrine parameters monitored throughout the entire 10-day period makes it unlikely that the lack of difference between groups in measured aspects of placental functions was due only to a brief period of GH withdrawal at the time of study.
Consistent with the failure of GH treatment to increase growth in normal fetuses is the failure of GH to markedly alter fetal metabolic profiles. In postnatal life, GH administration reduces glucose uptake and increases lypolysis (Davidson 1987) as well as increasing protein synthesis and decreasing urea production (Salomon et al. 1991) . In our study, GH-treated fetuses had reduced glucose uptake per kg fetus and decreased blood urea concentrations, both of which are consistent with the postnatal metabolic effects of GH. However, it is difficult to distinguish these possible GH effects from the altered metabolic profiles of larger fetuses of larger mothers with higher arterial oxygen contents secondary to higher haemoglobin concentrations. The lower blood urea concentrations in the GH-treated group were most likely to be secondary to similar lower maternal blood urea concentrations of well-nourished ewes, since urea crosses the placenta by simple diffusion, and fetal blood levels are thus directly related to those of the mother. This is supported by our finding of no difference in urea production per kg fetus between groups, as estimated by the relatively accurate measurement of [ 14 C]urea clearance. In contrast, fetal glucose uptake per kg fetus is reported to be unchanged with differing fetal size (Owens et al. 1987) . Thus the difference we observed may reflect true effects of GH on glucose uptake and insulin sensitivity, since GH is reported to decrease insulin sensitivity in fetal (Parkes & Bassett 1985) and postnatal lambs (Bellver et al. 1995) . The lack of effect of GH treatment on fetal levels of free fatty acids may seem surprising in view of previous evidence of the effects of GH on fetal fat deposition (Stevens & Alexander 1986) . However, their studies were conducted on hypophysectomised fetuses with relative obesity. The normal fetus has relatively little white fat at the stage in development which we studied, and brown fat appears resistant to lipolysis in utero because of placental factors (Ball et al. 1995) .
In summary, our study shows that pulsatile GH infusion to normal fetal sheep does not stimulate fetal growth, nor does it lead to substantial changes in fetal endocrine and metabolic profiles. These findings do not exclude a possible role for GH in the regulation of fetal growth and metabolism, since these experiments were only undertaken in normal fetuses. Since circulating GH concentrations are already extremely high in the normally growing fetus, it is possible that any role for GH in fetal growth and metabolism is already maximal in such fetuses, and cannot be further stimulated by additional GH. GH receptor concentrations are relatively low in fetal tissues, being approximately 30% of adult concentrations in the fetal liver at this age (Klempt et al. 1993) . Thus it is probable that the receptors are already fully saturated with endogenous GH or with ovine placental lactogen, which can also bind to the ovine GH receptor (Breier et al. 1994b) , and antagonises GH action in vitro (Herman et al. 1999) .
In addition, since fetal growth in late gestation is largely limited by nutrient availability, it is possible that, in the normal fetus, additional GH will have no effect on fetal growth unless nutrient availability is also altered. Hence it remains possible that in fetuses with reduced circulating GH concentrations or altered fetal nutrient availability, GH supplementation may result in a demonstrable change in fetal growth and metabolism. Studies examining these questions are currently underway in our laboratory.
